Targeting VEGF-Mediated Tumor Angiogenesis in Cancer Therapy
June 19 - 20, 2014 The New York Academy of Sciences
A decade after the first cancer drug targeting VEGF signaling in tumor blood vessel formation received approval by the US Food and Drug Administration (FDA), significant effort has been dedicated toward progressing the research, development, and clinical application of anti-angiogenic cancer therapies. Drawing on lessons learned from successes and failures, this conference will examine ways to improve cancer therapy by addressing urgent issues such as:
i. inherent /acquired resistance,
iii. enhanced invasiveness / metastasis, and
iv. lack of validated predictive and prognostic biomarkers.
Presentations, including a keynote lecture by Harold F. Dvorak, MD, will explore VEGF-dependent and alternative mechanisms of angiogenesis. “Point–Counterpoint” debates between leading experts will aim to resolve controversies regarding the function of vascular normalization, treatment-induced metastasis, and the validity of hypertension as a physiological biomarker.